TA-8995

DRUG8 trials

Sponsors

Tanabe Pharma Corporation, Xention Ltd

Conditions

DyslipidaemiaDyslipidemiaElevated Lp(a)Pharmacokinetic Interactions

Phase 1

Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 With Single, Escalating Doses in Healthy Subjects

CompletedNCT01878474

Tanabe Pharma CorporationDyslipidemia

Start: 2008-03-31End: 2009-06-30Updated: 2013-06-17

Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects

CompletedNCT01879020

Tanabe Pharma CorporationDyslipidemia

Start: 2009-08-31End: 2010-06-30Updated: 2013-06-17

A Preliminary Drug Drug Interaction Study With TA-8995

CompletedNCT02124954

Xention LtdPharmacokinetic Interactions

Start: 2014-05-31End: 2014-07-31Updated: 2016-10-03

A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)

CompletedNCT02241772

Xention LtdElevated Lp(a)

Start: 2014-09-30End: 2015-02-28Updated: 2015-02-16

Study of the Electrocardiographic Effects of TA-8995

CompletedNCT02241759

Xention LtdDyslipidaemia

Start: 2014-08-31End: 2014-12-31Updated: 2015-02-16

ADME Study in Healthy Male Subjects With TA-8995

CompletedNCT02408055

Xention LtdDyslipidemia

Start: 2015-06-30End: 2015-08-31Updated: 2016-10-03

Bioequivalence Study of Capsule and Tablet Formulations of TA-8995

CompletedNCT02523391

Xention LtdDyslipidaemia

Start: 2015-07-31End: 2015-11-30Updated: 2016-01-29

Phase 2

TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)

CompletedNCT01970215

Xention LtdDyslipidemia

Start: 2013-08-31End: 2014-07-31Updated: 2014-08-21

Related Papers

Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition

European Heart Journal - Cardiovascular Pharmacotherapy2022-10-2515 citations

Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses.

2016-06-2530 citations

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.

2015-06-02171 citations